| |
This website contains ‘forward-looking statements’ about the products, products under development and the business prospects of BioMarin Pharmaceutical Inc. (‘BioMarin’). These statements can be identified by the use of terminology such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘plans,’ ‘may,’ ‘will,’ ‘projects,’ ‘continues,’ ‘estimates,’ ‘potential,’ ‘opportunity,’ and similar terminology as well as any presentation of events to occur after the date a particular page was last updated. In particular, there are forward-looking statements regarding BioMarin's expectations as to commercialization activities of products, BioMarin’s financial performance and results of operations, the timing and success of clinical and preclinical studies of product candidates, and the potential timing and success of BioMarin's product programs through their individual product development and regulatory approval processes.
Actual results may differ materially from those
contained in these forward-looking statements as
a result of a number of factors including, but not
limited to: the success of our commercialization
efforts, the effect of competing products, the actual
results and timing of preclinical and clinical trials,
manufacturing and other production issues, actions
by regulatory authorities, and those other factors
detailed in BioMarin's filings with the Securities
and Exchange Commission such as BioMarin's 10-K,
10-Q and 8-K reports. You are urged not to place
undue reliance on these forward-looking statements,
which speak only as of the date that they were last
updated. BioMarin is under no obligation, and expressly
disclaims any obligation, to update or alter any
forward-looking statement, whether as a result of
new information, future events or otherwise. |
|
